Drug Trial Radar · NCT05295732
The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
153
Actual
Start
Jun 21, 2022
Primary completion
Jun 17, 2024
Study completion Sep 23, 2024
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Mar 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind and vehicle-controlled Phase III study to evaluate the safety and efficacy of topical TMB-001 0.05% ointment for the treatment of congenital ichthyosis (CI) in subjects with either the RXLI or ARCI subtypes. In addition, a subset of preselected centers will recruit subjects in parallel with either the RXLI or ARCI subtypes for enrollment into an Optional Maximal Use arm for evaluation of the systemic exposure and safety of topical TMB-001 0.05% ointment for the treatment of CI. The Phase III Study is designed in three periods: \- Period 1 - Induction (3 weeks): At the beginning of the 3-week Induction Period, eligible subjects will be randomized (2:1 ratio) to either TMB-001 0.05% once-a-day (QD) or Vehicle QD treatment, with use of mandatory standardized bland emollient (Cetaphil™) provided by the Sponsor. \- Period 2 - Treatment (9 weeks): The dosing frequency in the 9-week treatment period will be increased in each treatment group to TMB-001 0.05% BID or Vehicle BID. Mandatory bland emollient will be discontinued. \- Period 3 - Maintenance (12 weeks): At Week 12, eligible subjects in the TMB-001 treatment group will be randomized (1:1 ratio) to an open-label treatment with TMB-001 0.05% BID or TMB-001 0.05% QD. To be eligible, subjects must have achieved a ≥1-point reduction in IGA score from Baseline. Subjects with less than a 1-point reduction in IGA score from Baseline will be discontinued from the study. Vehicle-treated subjects who achieved \<1-point reduction in IGA score from Baseline are eligible to cross over to the TMB-001 0.05% BID treatment group. Subjects with a ≥1-point reduction in IGA score from Baseline on vehicle will be discontinued from the study. Subjects at the end of the study or subjects discontinued from the study at any time will be followed-up for additional 2 weeks for AEs.
Conditions
- Ichthyosis
Interventions
TMB-001Drug
Topical TMB-001 0.05% QD/BID
Matching VehicleDrug
Topical Vehicle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Investigator Global Assessment (IGA) ScoreTime frame: 12 weeks
Locations
35 sites in 5 countries. Site status is shown where the registry gives one.
U.S. Dermatology Partners
Phoenix, Arizona
Stanford University School of Medicine
Palo Alto, California
About Skin Dermatology
Centennial, Colorado
Yale Center for Clinical Investigation
New Haven, Connecticut
Department of Dermatology and Cutaneous Surgery, University of Miami
Miami, Florida
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
The Indiana Clinical Trials Center
Plainfield, Indiana
Associated Skincare Specialists
New Brighton, Minnesota
University of Mississippi Medical Center (UMMC)
Jackson, Mississippi
Wake Forest University Health Sciences
Winston-Salem, North Carolina
Optima Research
Boardman, Ohio
Children's Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Austin Institute for Clinical Research
Houston, Texas
Austin Institute for Clinical Research, Inc.
Pflugerville, Texas
Virginia Clinical Research-Pariser Dermatology Specialists
Norfolk, Virginia
North Sound Dermatology
Mill Creek, Washington
Stollery Children's Hospital
Edmonton, Alberta, Canada
Dr. Chih-ho Hong Medical Inc.
Surrey, British Columbia, Canada
Wiseman Dermatology Research Inc.
Winnipeg, Manitoba, Canada
SickKids Hospital
Toronto, Ontario, Canada
Hôpital Femme Mère Enfant
Bron, France
CHU de Nantes Hotel Dieu
Nantes, France
Hopital Necker APHP
Paris, France
Hopital Larrey CHU Toulouse
Toulouse, France
Charité - Universitätsmedizin Berlin
Berlin, Germany
Universitätsklinikum Erlangen
Erlangen, Germany
Katholisches Kinderkrankenhaus Wilhelmstift GmbH
Hamburg, Germany
Münster University Hospital
Münster, Germany
U.O. di Dermatologia e Venereologia Universitaria
Bari, Italy
U.O. di Dermatologia Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale
Bologna, Italy
Ambulatorio di Malattie Rare Dermatologiche e Immunopatologia Cutanea
Florence, Italy
Fondazione IRCCS Ospedale Maggiore Policlinico Milano, Area Materno Infantile - SC pediatria Pneumoinfettivologia
Milan, Italy
U.O.C. di Dermatologia Dipartimento Pediatrico Universitario Ospedaliero
Roma, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.